Regional cerebral tau deposition increases with the AD prognosis and correlates with the degree of cognitive decline, and it was reported that the regional uptake of flortaucipir, one of the first-generation tau PET tracers, is correlated with cognitive tests (4). The gene discussed is MAPT; the disease is Alzheimer disease.